Turkey
October 2012
Key Market Facts
- Turkey's pharmaceutical market was valued at approximately TRY 18-20 billion ($6.5-7.5 billion) in 2015, with rapid growth driven by a large and young population, expanding health insurance coverage, and rising chronic disease rates.
- Abdi Ibrahim, Eczacibasi, Deva Holding, Santa Farma, and Nobel Ilac are among Turkey's major domestic pharmaceutical manufacturers, with the industry employing over 20,000 people and exporting to more than 100 countries.
- Regulatory authority: TITCK (Turkish Medicines and Medical Devices Agency) governs pharmaceutical regulation in Turkey, having undergone significant modernisation to align with EU regulatory standards as part of Turkey's EU accession process.
- Turkey's pharmaceutical sector has developed a strong generics manufacturing base, producing approximately 60-65% of domestic pharmaceutical needs locally by volume, supported by government incentives for local production.
- Currency depreciation and government drug price controls have been persistent challenges for Turkey's pharmaceutical market since 2011, with ongoing reductions in the exchange rate reference used for pricing eroding manufacturer revenues.
Back
